Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015, 55642-55646 [2015-23199]
Download as PDF
<![CDATA[
55642
Federal Register / Vol. 80, No. 179 / Wednesday, September 16, 2015 / Notices
Jean Sonneman,
Bureau of Land Management, Information
Collection Clearance Officer, Bureau of Land
Management.
[FR Doc. 2015–23257 Filed 9–15–15; 8:45 am]
BILLING CODE 4310–84–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–418F]
Final Adjusted Aggregate Production
Quotas for Schedule I and II Controlled
Substances and Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2015
Drug Enforcement
Administration, Department of Justice.
ACTION: Final order.
AGENCY:
This final order establishes
the final adjusted 2015 aggregate
production quotas for controlled
substances in schedules I and II of the
Controlled Substances Act and the
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
SUMMARY:
This order is effective September
16, 2015.
FOR FURTHER INFORMATION CONTACT: John
R. Scherbenske, Office of Diversion
Control, Drug Enforcement
Administration, 8701 Morrissette Drive,
Springfield, Virginia 22152; Telephone:
(202) 598–6812.
SUPPLEMENTARY INFORMATION:
DATES:
asabaliauskas on DSK7TPTVN1PROD with NOTICES
Legal Authority
The Drug Enforcement
Administration (DEA) implements and
enforces titles II and III of the
Comprehensive Drug Abuse Prevention
and Control Act of 1970, as amended. 21
U.S.C. 801–971. Titles II and III are
referred to as the ‘‘Controlled
Substances Act’’ and the ‘‘Controlled
Substances Import and Export Act,’’
respectively, and are collectively
referred to as the ‘‘Controlled
Substances Act’’ or the ‘‘CSA’’ for the
purposes of this action. The DEA
publishes the implementing regulations
for these statutes in title 21 of the Code
of Federal Regulations (CFR), chapter II.
The CSA and its implementing
regulations are designed to prevent,
detect, and eliminate the diversion of
controlled substances and listed
chemicals into the illicit market while
providing for the legitimate medical,
scientific, research, and industrial needs
of the United States. Controlled
VerDate Sep<11>2014
18:18 Sep 15, 2015
Jkt 235001
substances have the potential for abuse
and dependence and are controlled to
protect the public health and safety.
Section 306 of the CSA (21 U.S.C.
826) requires the Attorney General to
establish aggregate production quotas
for each basic class of controlled
substance listed in schedules I and II
and for ephedrine, pseudoephedrine,
and phenylpropanolamine. This
responsibility has been delegated to the
Administrator of the DEA. 28 CFR
0.100(b).
Background
The DEA established the initial 2015
aggregate production quotas for
controlled substances in schedules I and
II and the assessment of annual needs
for the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine on September 8,
2014. 79 FR 53216. That notice stated
that the DEA could adjust, as needed,
the established aggregate production
quotas and assessment of annual needs
in accordance with 21 CFR 1303.13 and
21 CFR 1315.13. The proposed adjusted
2015 aggregate production quotas for
controlled substances in schedules I and
II and assessment of annual needs for
the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine were
subsequently published in the Federal
Register on July 8, 2015, 80 FR 39156,
in consideration of the outlined criteria.
All interested persons were invited to
comment on or object to the proposed
adjusted 2015 aggregate production
quotas and assessment of annual needs
on or before August 7, 2015.
Analysis for Final Adjusted 2015
Aggregate Production Quotas and
Assessment of Annual Needs
Consideration has been given to the
criteria outlined in the July 8, 2015,
notice of proposed adjusted aggregate
production quotas and assessment of
annual needs, 80 FR 39156, in
accordance with 21 CFR 1303.13 and 21
CFR 1315.13. Five companies submitted
timely comments regarding twelve
schedule I and II controlled substances.
These comments suggested that the
proposed adjusted aggregate production
quotas for codeine (for sale), fentanyl,
gamma hydroxybutric acid,
hydrocodone (for sale), methadone,
methadone intermediate,
methylphenidate, morphine (for
conversion), oripavine, oxycodone (for
sale), oxymorphone (for conversion),
and oxymorphone (for sale) were
insufficient to provide for the estimated
medical, scientific, research, and
industrial needs of the United States, for
export requirements, and for the
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
establishment and maintenance of
reserve stocks. The DEA did not receive
any comments related to the proposal
not to adjust the 2015 assessment of
annual needs for ephedrine,
pseudoephedrine, and
phenylpropanolamine.
In accordance with 21 CFR 1303.13,
the DEA has taken into consideration
the above comments along with the
relevant 2014 year-end inventories,
initial 2015 manufacturing and import
quotas, 2015 export requirements, actual
and projected 2015 sales, research and
product development requirements, and
the additional quota applications
received. Upon consideration of the
above, the Administrator determined
that the proposed adjusted 2015
aggregate production quotas for
dihydroetorphine, ethylmorphine,
etorphine HCl, racemethorphan,
racemorphan, methylphenidate, and
oxycodone (for sale) required additional
consideration and hereby further adjusts
the proposed 2015 aggregate production
quotas for these substances. Regarding
codeine (for sale), fentanyl, gamma
hydroxybutric acid, hydrocodone (for
sale), methadone, methadone
intermediate, morphine (for
conversion), oripavine, oxymorphone
(for conversion), and oxymorphone (for
sale) the Administrator hereby
determines that the proposed adjusted
2015 aggregate production quotas for
these substances as published in the
Federal Register on July 8, 2015, 80 FR
39156, are sufficient to meet the current
2015 estimated medical, scientific,
research, and industrial needs of the
United States and to provide for
adequate reserve stock.
As described in the previously
published notice establishing the 2015
aggregate production quotas and
assessment of annual needs, the DEA
has specifically considered that
inventory allowances granted to
individual manufacturers may not
always result in the availability of
sufficient quantities to maintain an
adequate reserve stock pursuant to 21
U.S.C. 826(a), as intended. See 21 CFR
1303.24. This would be concerning if a
natural disaster or other unforeseen
event resulted in substantial disruption
to the amount of controlled substances
available to provide for legitimate
public need. As such, the DEA included
in all schedule II aggregate production
quotas, and certain schedule I aggregate
production quotas, an additional 25% of
the estimated medical, scientific, and
research needs as part of the amount
necessary to ensure the establishment
and maintenance of reserve stocks. The
final established aggregate production
quotas will reflect these included
E:\FR\FM\16SEN1.SGM
16SEN1
Federal Register / Vol. 80, No. 179 / Wednesday, September 16, 2015 / Notices
amounts. This action will not affect the
ability of manufacturers to maintain
inventory allowances as specified by
regulation. The DEA expects that
maintaining this reserve in certain
established aggregate production quotas
will mitigate adverse public effects if an
unforeseen event results in substantial
disruption to the amount of controlled
substances available to provide for
legitimate public need, as determined
by the DEA. The DEA does not
anticipate utilizing the reserve in the
absence of these circumstances.
Pursuant to the above, the
Administrator hereby finalizes the 2015
55643
aggregate production quotas for the
following schedule I and II controlled
substances and the 2015 assessment of
annual needs for the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine, expressed in
grams of anhydrous acid or base, as
follows:
Final adjusted
2015 quotas
(g)
Basic class
asabaliauskas on DSK7TPTVN1PROD with NOTICES
Schedule I
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR–144) .............................................................................
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ...............................................................
[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ–2201) ...............................................................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) .................................................................................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) .............................................................................................
1-(1-Phenylcyclohexyl)pyrrolidine ..................................................................................................................................................
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ......................................................................................................................
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) .....................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine .............................................................................................................................................
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200) ........................................................................................................
1-Butyl-3-(1-naphthoyl)indole (JWH–073) .....................................................................................................................................
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR–18 and RCS–8) ...................................................................................
1-Hexyl-3-(1-naphthoyl)indole (JWH–019) ....................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine .....................................................................................................................................
1-Pentyl-3-(1-naphthoyl)indole (JWH–018 and AM678) ...............................................................................................................
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH–203) .....................................................................................................................
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250) .................................................................................................................
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–398) .....................................................................................................................
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–122) ....................................................................................................................
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19, RCS–4) .............................................................................................................
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH–081) ................................................................................................................
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C–P) ...............................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E) ....................................................................................................................
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D) .................................................................................................................
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N) ...................................................................................................................
2-(2,5-Dimethoxyphenyl)ethanamine (2C–H) ................................................................................................................................
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B–NBOMe; 2C–B–NBOMe; 25B; Cimbi-36) ................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C) ..................................................................................................................
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C–NBOMe; 2C–C–NBOMe; 25C; Cimbi-82) ...............
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I) .......................................................................................................................
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C–I–NBOMe; 25I; Cimbi-5) ..........................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone) ...................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (DOET) ................................................................................................................................
2,5-Dimethoxy-4-n-propylthiophenethylamine ...............................................................................................................................
2,5-Dimethoxyamphetamine ..........................................................................................................................................................
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2) .........................................................................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4) ..................................................................................................
3,4,5-Trimethoxyamphetamine ......................................................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ......................................................................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) ...........................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .......................................................................................................................
3,4-Methylenedioxy-N-methylcathinone (methylone) ....................................................................................................................
3,4-Methylenedioxypyrovalerone (MDPV) .....................................................................................................................................
3-Fluoro-N-methylcathinone (3–FMC) ...........................................................................................................................................
3-Methylfentanyl .............................................................................................................................................................................
3-Methylthiofentanyl .......................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ...........................................................................................................................
4-Fluoro-N-methylcathinone (4–FMC) ...........................................................................................................................................
4-Methoxyamphetamine ................................................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................................................................
4-Methylaminorex ..........................................................................................................................................................................
4-Methyl-N-ethylcathinone (4–MEC) .............................................................................................................................................
4-Methyl-N-methylcathinone (mephedrone) ..................................................................................................................................
4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) .........................................................................................................................
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ...................................................................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8-homolog) ....................
5-Methoxy-3,4-methylenedioxyamphetamine ................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................................
5-Methoxy-N,N-dimethyltryptamine ...............................................................................................................................................
Acetyl-alpha-methylfentanyl ...........................................................................................................................................................
VerDate Sep<11>2014
18:18 Sep 15, 2015
Jkt 235001
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
E:\FR\FM\16SEN1.SGM
16SEN1
25
25
15
25
25
10
45
45
15
45
45
45
45
2
45
45
45
45
45
45
45
30
30
30
30
30
25
30
25
30
15
15
25
25
25
30
30
25
55
50
40
50
35
25
2
2
25
25
25
100
25
25
25
45
25
68
53
25
25
25
2
55644
Federal Register / Vol. 80, No. 179 / Wednesday, September 16, 2015 / Notices
Final adjusted
2015 quotas
(g)
asabaliauskas on DSK7TPTVN1PROD with NOTICES
Basic class
Acetyldihydrocodeine .....................................................................................................................................................................
Acetylmethadol ..............................................................................................................................................................................
Allylprodine ....................................................................................................................................................................................
Alphacetylmethadol ........................................................................................................................................................................
alpha-Ethyltryptamine ....................................................................................................................................................................
Alphameprodine .............................................................................................................................................................................
Alphamethadol ...............................................................................................................................................................................
alpha-Methylfentanyl ......................................................................................................................................................................
alpha-Methylthiofentanyl ................................................................................................................................................................
alpha-Methyltryptamine (AMT) ......................................................................................................................................................
alpha-Pyrrolidinobutiophenone (a-PBP) ........................................................................................................................................
alpha-Pyrrolidinopentiophenone (a-PVP) ......................................................................................................................................
Aminorex ........................................................................................................................................................................................
Benzylmorphine .............................................................................................................................................................................
Betacetylmethadol .........................................................................................................................................................................
beta-Hydroxy-3-methylfentanyl ......................................................................................................................................................
beta-Hydroxyfentanyl .....................................................................................................................................................................
Betameprodine ...............................................................................................................................................................................
Betamethadol .................................................................................................................................................................................
Betaprodine ....................................................................................................................................................................................
Bufotenine ......................................................................................................................................................................................
Cathinone .......................................................................................................................................................................................
Codeine methylbromide .................................................................................................................................................................
Codeine-N-oxide ............................................................................................................................................................................
Desomorphine ................................................................................................................................................................................
Diethyltryptamine ...........................................................................................................................................................................
Difenoxin ........................................................................................................................................................................................
Dihydromorphine ............................................................................................................................................................................
Dimethyltryptamine ........................................................................................................................................................................
Dipipanone .....................................................................................................................................................................................
Fenethylline ....................................................................................................................................................................................
gamma-Hydroxybutyric acid ..........................................................................................................................................................
Heroin ............................................................................................................................................................................................
Hydromorphinol ..............................................................................................................................................................................
Hydroxypethidine ...........................................................................................................................................................................
Ibogaine .........................................................................................................................................................................................
Lysergic acid diethylamide (LSD) ..................................................................................................................................................
Marihuana ......................................................................................................................................................................................
Mescaline .......................................................................................................................................................................................
Methaqualone ................................................................................................................................................................................
Methcathinone ...............................................................................................................................................................................
Methyldesorphine ...........................................................................................................................................................................
Methyldihydromorphine ..................................................................................................................................................................
Morphine methylbromide ...............................................................................................................................................................
Morphine methylsulfonate ..............................................................................................................................................................
Morphine-N-oxide ..........................................................................................................................................................................
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ..................................................................................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB–PINACA) ...............................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB–FUBINACA) ...................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB–CHMINACA) .............................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB–PINACA) .......................................................
N,N-Dimethylamphetamine ............................................................................................................................................................
Naphthylpyrovalerone (naphyrone) ...............................................................................................................................................
N-Benzylpiperazine ........................................................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ..................................................................................................................................................
N-Ethylamphetamine .....................................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................................................................
Noracymethadol .............................................................................................................................................................................
Norlevorphanol ...............................................................................................................................................................................
Normethadone ...............................................................................................................................................................................
Normorphine ..................................................................................................................................................................................
Para-fluorofentanyl .........................................................................................................................................................................
Parahexyl .......................................................................................................................................................................................
Phenomorphan ..............................................................................................................................................................................
Pholcodine .....................................................................................................................................................................................
Psilocybin .......................................................................................................................................................................................
Psilocyn ..........................................................................................................................................................................................
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB–22; 5F–PB–22) ................................................................
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB–22; QUPIC) .................................................................................................
Tetrahydrocannabinols ..................................................................................................................................................................
Thiofentanyl ...................................................................................................................................................................................
Tilidine ............................................................................................................................................................................................
VerDate Sep<11>2014
18:18 Sep 15, 2015
Jkt 235001
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
E:\FR\FM\16SEN1.SGM
16SEN1
2
2
2
2
25
2
2
2
2
25
25
25
25
2
2
2
2
2
4
2
3
70
5
305
25
25
11,000
3,990,000
35
5
5
70,250,000
50
2
2
5
35
658,000
25
10
25
5
2
5
5
350
25
25
25
15
15
25
25
25
5
24
24
2
52
2
40
5
5
2
5
30
30
25
25
511,250
2
25
Federal Register / Vol. 80, No. 179 / Wednesday, September 16, 2015 / Notices
55645
Final adjusted
2015 quotas
(g)
Basic class
Trimeperidine .................................................................................................................................................................................
2
Schedule II
1-Phenylcyclohexylamine ..............................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ..............................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) ...................................................................................................................................
Alfentanil ........................................................................................................................................................................................
Alphaprodine ..................................................................................................................................................................................
Amobarbital ....................................................................................................................................................................................
Amphetamine (for conversion) ......................................................................................................................................................
Amphetamine (for sale) .................................................................................................................................................................
Carfentanil ......................................................................................................................................................................................
Cocaine ..........................................................................................................................................................................................
Codeine (for conversion) ...............................................................................................................................................................
Codeine (for sale) ..........................................................................................................................................................................
Dextropropoxyphene ......................................................................................................................................................................
Dihydrocodeine ..............................................................................................................................................................................
Dihydroetorphine ............................................................................................................................................................................
Diphenoxylate (for conversion) ......................................................................................................................................................
Diphenoxylate (for sale) .................................................................................................................................................................
Ecgonine ........................................................................................................................................................................................
Ethylmorphine ................................................................................................................................................................................
Etorphine hydrochloride .................................................................................................................................................................
Fentanyl .........................................................................................................................................................................................
Glutethimide ...................................................................................................................................................................................
Hydrocodone (for conversion) .......................................................................................................................................................
Hydrocodone (for sale) ..................................................................................................................................................................
Hydromorphone .............................................................................................................................................................................
Isomethadone ................................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ..................................................................................................................................................
Levomethorphan ............................................................................................................................................................................
Levorphanol ...................................................................................................................................................................................
Lisdexamfetamine ..........................................................................................................................................................................
Meperidine .....................................................................................................................................................................................
Meperidine Intermediate-A ............................................................................................................................................................
Meperidine Intermediate-B ............................................................................................................................................................
Meperidine Intermediate-C ............................................................................................................................................................
Metazocine .....................................................................................................................................................................................
Methadone (for sale) .....................................................................................................................................................................
Methadone Intermediate ................................................................................................................................................................
Methamphetamine .........................................................................................................................................................................
5
5
2,687,500
17,750
3
25,125
21,875,000
37,500,000
19
275,000
50,000,000
63,900,000
45
226,375
3
75,000
1,337,500
174,375
5
3
2,300,000
3
137,500
99,625,000
7,000,000
5
4
30
7,125
29,750,000
6,250,000
6
32
6
19
31,875,000
34,375,000
2,061,375
asabaliauskas on DSK7TPTVN1PROD with NOTICES
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine
mostly for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)]
Methylphenidate .............................................................................................................................................................................
Morphine (for conversion) ..............................................................................................................................................................
Morphine (for sale) ........................................................................................................................................................................
Nabilone .........................................................................................................................................................................................
Noroxymorphone (for conversion) .................................................................................................................................................
Noroxymorphone (for sale) ............................................................................................................................................................
Opium (powder) .............................................................................................................................................................................
Opium (tincture) .............................................................................................................................................................................
Oripavine ........................................................................................................................................................................................
Oxycodone (for conversion) ..........................................................................................................................................................
Oxycodone (for sale) .....................................................................................................................................................................
Oxymorphone (for conversion) ......................................................................................................................................................
Oxymorphone (for sale) .................................................................................................................................................................
Pentobarbital ..................................................................................................................................................................................
Phenazocine ..................................................................................................................................................................................
Phencyclidine .................................................................................................................................................................................
Phenmetrazine ...............................................................................................................................................................................
Phenylacetone ...............................................................................................................................................................................
Racemethorphan ...........................................................................................................................................................................
Racemorphan ................................................................................................................................................................................
Remifentanil ...................................................................................................................................................................................
Secobarbital ...................................................................................................................................................................................
Sufentanil .......................................................................................................................................................................................
Tapentadol .....................................................................................................................................................................................
Thebaine ........................................................................................................................................................................................
VerDate Sep<11>2014
18:18 Sep 15, 2015
Jkt 235001
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
E:\FR\FM\16SEN1.SGM
16SEN1
96,750,000
91,250,000
62,500,000
18,750
17,500,000
1,475,000
112,500
687,500
35,000,000
8,350,000
141,375,000
29,000,000
7,750,000
35,000,000
6
38
3
9,375,000
5
3
4,200
215,003
6,255
12,500,000
125,000,000
55646
Federal Register / Vol. 80, No. 179 / Wednesday, September 16, 2015 / Notices
Final adjusted
2015 quotas
(g)
Basic class
List I Chemicals
Ephedrine (for conversion) ............................................................................................................................................................
Ephedrine (for sale) .......................................................................................................................................................................
Phenylpropanolamine (for conversion) ..........................................................................................................................................
Phenylpropanolamine (for sale) .....................................................................................................................................................
Pseudoephedrine (for conversion) ................................................................................................................................................
Pseudoephedrine (for sale) ...........................................................................................................................................................
Aggregate production quotas for all
other schedule I and II controlled
substances included in 21 CFR 1308.11
and 1308.12 remain at zero.
Dated: September 10, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015–23199 Filed 9–15–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Office of the Secretary
Establishing a Minimum Wage for
Contractors, Notice of Rate Change in
Effect as of January 1, 2016
Wage and Hour Division,
Department of Labor.
ACTION: Notice.
AGENCY:
The Wage and Hour Division
(WHD) of the U.S. Department of Labor
(the Department) is issuing this notice to
announce the applicable minimum
wage rate to be paid to workers
performing work on or in connection
with Federal contracts covered by
Executive Order 13658, beginning
January 1, 2016.
Executive Order 13658, Establishing a
Minimum Wage for Contractors (the
Executive Order or the Order), was
signed by President Barack Obama on
February 12, 2014, and raised the hourly
minimum wage paid by contractors to
workers performing work on covered
Federal contracts to: $10.10 per hour,
beginning January 1, 2015; and
beginning January 1, 2016, and annually
thereafter, an amount determined by the
Secretary of Labor (the Secretary) in
accordance with the methodology set
forth in the Order. See 79 FR 9851. The
Secretary’s determination of the
Executive Order minimum wage rate
also affects the minimum hourly cash
wage that must be paid to tipped
employees performing work on or in
connection with covered contracts
beginning January 1, 2016. See 79 FR
9851–52. The Secretary is required to
provide notice to the public of the new
minimum wage rate at least 90 days
asabaliauskas on DSK7TPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:18 Sep 15, 2015
Jkt 235001
before such rate is to take effect. See 79
FR 9851.
Pursuant to Executive Order 13658
and its implementing regulations at 29
CFR part 10, notice is hereby given that
beginning January 1, 2016, the
Executive Order minimum wage rate
that generally must be paid to workers
performing work on or in connection
with covered contracts is $10.15 per
hour. Notice is also hereby given that,
beginning January 1, 2016, the required
minimum cash wage that generally must
be paid to tipped employees performing
work on or in connection with covered
contracts is $5.85 per hour.
DATES: This notice is effective on
September 16, 2015.
FOR FURTHER INFORMATION CONTACT:
Robert Waterman, Acting Director,
Division of Regulations, Legislation, and
Interpretation, Wage and Hour Division,
U.S. Department of Labor, Room S–
3502, 200 Constitution Avenue NW.,
Washington, DC 20210; telephone: (202)
693–0406 (this is not a toll-free
number). Copies of this notice may be
obtained in alternative formats (Large
Print, Braille, Audio Tape, or Disc),
upon request, by calling (202) 693–0023
(not a toll-free number). TTY/TTD
callers may dial toll-free (877) 889–5627
to obtain information or request
materials in alternative formats.
SUPPLEMENTARY INFORMATION:
I. Executive Order 13658 Background
and Requirements for Determining
Annual Increases to the Minimum
Wage Rate
Executive Order 13658 was signed by
President Barack Obama on February
12, 2014, and raised the hourly
minimum wage paid by contractors to
workers performing work on or in
connection with covered Federal
contracts to $10.10 per hour, beginning
January 1, 2015; and beginning January
1, 2016, and annually thereafter, an
amount determined by the Secretary
pursuant to the Order. See 79 FR 9851.
The Executive Order directed the
Secretary to issue regulations to
implement the Order’s requirements.
See 79 FR 9852. Accordingly, after
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
1,000,000
4,000,000
44,800,000
8,500,000
7,000
224,500,000
engaging in notice-and-comment
rulemaking, the Department published a
Final Rule on October 7, 2014 to
implement the Executive Order. See 79
FR 60634. The final regulations, set
forth at 29 CFR part 10, established
standards and procedures for
implementing and enforcing the
minimum wage protections of the
Order.
The Executive Order and its
implementing regulations require the
Secretary to determine the applicable
minimum wage rate to be paid to
workers performing work on or in
connection with covered contracts on an
annual basis, beginning January 1, 2016.
See 79 FR 9851; 29 CFR 10.1(a)(2),
10.5(a)(2), 10.12(a). Sections 2(a) and (b)
of the Order establish the methodology
that the Secretary must use to determine
the annual inflation-based increases to
the minimum wage rate. See 79 FR
9851. These provisions, which are
implemented in 29 CFR 10.5(b), explain
that the applicable minimum wage
determined by the Secretary for each
calendar year shall be:
(i) Not less than the amount in effect
on the date of such determination;
(ii) Increased from such amount by
the annual percentage increase in the
Consumer Price Index for Urban Wage
Earners and Clerical Workers (CPI–W)
(United States city average, all items,
not seasonally adjusted), or its successor
publication, as determined by the
Bureau of Labor Statistics (BLS); and
(iii) Rounded to the nearest multiple
of $0.05.
Section 2(b) of the Executive Order
further provides that, in calculating the
annual percentage increase in the CPI
for purposes of determining the new
minimum wage rate, the Secretary shall
compare such CPI for the most recent
month, quarter, or year available (as
selected by the Secretary prior to the
first year for which a minimum wage is
in effect) with the CPI for the same
month in the preceding year, the same
quarter in the preceding year, or the
preceding year, respectively. See 79 FR
9851. In order to calculate the annual
percentage increase in the CPI, the
Department elected in its Final Rule
E:\FR\FM\16SEN1.SGM
16SEN1
]]>Agencies
[Federal Register Volume 80, Number 179 (Wednesday, September 16, 2015)]
[Notices]
[Pages 55642-55646]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-23199]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-418F]
Final Adjusted Aggregate Production Quotas for Schedule I and II
Controlled Substances and Assessment of Annual Needs for the List I
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Final order.
-----------------------------------------------------------------------
SUMMARY: This final order establishes the final adjusted 2015 aggregate
production quotas for controlled substances in schedules I and II of
the Controlled Substances Act and the assessment of annual needs for
the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine.
DATES: This order is effective September 16, 2015.
FOR FURTHER INFORMATION CONTACT: John R. Scherbenske, Office of
Diversion Control, Drug Enforcement Administration, 8701 Morrissette
Drive, Springfield, Virginia 22152; Telephone: (202) 598-6812.
SUPPLEMENTARY INFORMATION:
Legal Authority
The Drug Enforcement Administration (DEA) implements and enforces
titles II and III of the Comprehensive Drug Abuse Prevention and
Control Act of 1970, as amended. 21 U.S.C. 801-971. Titles II and III
are referred to as the ``Controlled Substances Act'' and the
``Controlled Substances Import and Export Act,'' respectively, and are
collectively referred to as the ``Controlled Substances Act'' or the
``CSA'' for the purposes of this action. The DEA publishes the
implementing regulations for these statutes in title 21 of the Code of
Federal Regulations (CFR), chapter II. The CSA and its implementing
regulations are designed to prevent, detect, and eliminate the
diversion of controlled substances and listed chemicals into the
illicit market while providing for the legitimate medical, scientific,
research, and industrial needs of the United States. Controlled
substances have the potential for abuse and dependence and are
controlled to protect the public health and safety.
Section 306 of the CSA (21 U.S.C. 826) requires the Attorney
General to establish aggregate production quotas for each basic class
of controlled substance listed in schedules I and II and for ephedrine,
pseudoephedrine, and phenylpropanolamine. This responsibility has been
delegated to the Administrator of the DEA. 28 CFR 0.100(b).
Background
The DEA established the initial 2015 aggregate production quotas
for controlled substances in schedules I and II and the assessment of
annual needs for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine on September 8, 2014. 79 FR 53216. That notice
stated that the DEA could adjust, as needed, the established aggregate
production quotas and assessment of annual needs in accordance with 21
CFR 1303.13 and 21 CFR 1315.13. The proposed adjusted 2015 aggregate
production quotas for controlled substances in schedules I and II and
assessment of annual needs for the list I chemicals ephedrine,
pseudoephedrine, and phenylpropanolamine were subsequently published in
the Federal Register on July 8, 2015, 80 FR 39156, in consideration of
the outlined criteria. All interested persons were invited to comment
on or object to the proposed adjusted 2015 aggregate production quotas
and assessment of annual needs on or before August 7, 2015.
Analysis for Final Adjusted 2015 Aggregate Production Quotas and
Assessment of Annual Needs
Consideration has been given to the criteria outlined in the July
8, 2015, notice of proposed adjusted aggregate production quotas and
assessment of annual needs, 80 FR 39156, in accordance with 21 CFR
1303.13 and 21 CFR 1315.13. Five companies submitted timely comments
regarding twelve schedule I and II controlled substances. These
comments suggested that the proposed adjusted aggregate production
quotas for codeine (for sale), fentanyl, gamma hydroxybutric acid,
hydrocodone (for sale), methadone, methadone intermediate,
methylphenidate, morphine (for conversion), oripavine, oxycodone (for
sale), oxymorphone (for conversion), and oxymorphone (for sale) were
insufficient to provide for the estimated medical, scientific,
research, and industrial needs of the United States, for export
requirements, and for the establishment and maintenance of reserve
stocks. The DEA did not receive any comments related to the proposal
not to adjust the 2015 assessment of annual needs for ephedrine,
pseudoephedrine, and phenylpropanolamine.
In accordance with 21 CFR 1303.13, the DEA has taken into
consideration the above comments along with the relevant 2014 year-end
inventories, initial 2015 manufacturing and import quotas, 2015 export
requirements, actual and projected 2015 sales, research and product
development requirements, and the additional quota applications
received. Upon consideration of the above, the Administrator determined
that the proposed adjusted 2015 aggregate production quotas for
dihydroetorphine, ethylmorphine, etorphine HCl, racemethorphan,
racemorphan, methylphenidate, and oxycodone (for sale) required
additional consideration and hereby further adjusts the proposed 2015
aggregate production quotas for these substances. Regarding codeine
(for sale), fentanyl, gamma hydroxybutric acid, hydrocodone (for sale),
methadone, methadone intermediate, morphine (for conversion),
oripavine, oxymorphone (for conversion), and oxymorphone (for sale) the
Administrator hereby determines that the proposed adjusted 2015
aggregate production quotas for these substances as published in the
Federal Register on July 8, 2015, 80 FR 39156, are sufficient to meet
the current 2015 estimated medical, scientific, research, and
industrial needs of the United States and to provide for adequate
reserve stock.
As described in the previously published notice establishing the
2015 aggregate production quotas and assessment of annual needs, the
DEA has specifically considered that inventory allowances granted to
individual manufacturers may not always result in the availability of
sufficient quantities to maintain an adequate reserve stock pursuant to
21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be
concerning if a natural disaster or other unforeseen event resulted in
substantial disruption to the amount of controlled substances available
to provide for legitimate public need. As such, the DEA included in all
schedule II aggregate production quotas, and certain schedule I
aggregate production quotas, an additional 25% of the estimated
medical, scientific, and research needs as part of the amount necessary
to ensure the establishment and maintenance of reserve stocks. The
final established aggregate production quotas will reflect these
included
[[Page 55643]]
amounts. This action will not affect the ability of manufacturers to
maintain inventory allowances as specified by regulation. The DEA
expects that maintaining this reserve in certain established aggregate
production quotas will mitigate adverse public effects if an unforeseen
event results in substantial disruption to the amount of controlled
substances available to provide for legitimate public need, as
determined by the DEA. The DEA does not anticipate utilizing the
reserve in the absence of these circumstances.
Pursuant to the above, the Administrator hereby finalizes the 2015
aggregate production quotas for the following schedule I and II
controlled substances and the 2015 assessment of annual needs for the
list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine,
expressed in grams of anhydrous acid or base, as follows:
------------------------------------------------------------------------
Final adjusted
Basic class 2015 quotas (g)
------------------------------------------------------------------------
Schedule I
------------------------------------------------------------------------
(1-Pentyl-1H-indol-3-yl)(2,2,3,3- 25
tetramethylcyclopropyl)methanone (UR-144)...........
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- 25
tetramethylcyclopropyl)methanone (XLR11)............
[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1- 15
yl)methanone (THJ-2201).............................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one 25
(butylone)..........................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one 25
(pentylone).........................................
1-(1-Phenylcyclohexyl)pyrrolidine.................... 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201).... 45
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)... 45
1-[1-(2-Thienyl)cyclohexyl]piperidine................ 15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH- 45
200)................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073).............. 45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR- 45
18 and RCS-8).......................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019).............. 45
1-Methyl-4-phenyl-4-propionoxypiperidine............. 2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)... 45
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).... 45
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)... 45
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398).... 45
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122).... 45
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) 45
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081).. 45
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P).. 30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)..... 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D).... 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N).... 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)............. 30
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2- 25
methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe;
25B; Cimbi-36)......................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C).... 30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2- 25
methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe;
25C; Cimbi-82)......................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)...... 30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2- 15
methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe;
25I; Cimbi-5).......................................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone).... 15
2,5-Dimethoxy-4-ethylamphetamine (DOET).............. 25
2,5-Dimethoxy-4-n-propylthiophenethylamine........... 25
2,5-Dimethoxyamphetamine............................. 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T- 30
2)..................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine 30
(2C-T-4)............................................
3,4,5-Trimethoxyamphetamine.......................... 25
3,4-Methylenedioxyamphetamine (MDA).................. 55
3,4-Methylenedioxymethamphetamine (MDMA)............. 50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)......... 40
3,4-Methylenedioxy-N-methylcathinone (methylone)..... 50
3,4-Methylenedioxypyrovalerone (MDPV)................ 35
3-Fluoro-N-methylcathinone (3-FMC)................... 25
3-Methylfentanyl..................................... 2
3-Methylthiofentanyl................................. 2
4-Bromo-2,5-dimethoxyamphetamine (DOB)............... 25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)........... 25
4-Fluoro-N-methylcathinone (4-FMC)................... 25
4-Methoxyamphetamine................................. 100
4-Methyl-2,5-dimethoxyamphetamine (DOM).............. 25
4-Methylaminorex..................................... 25
4-Methyl-N-ethylcathinone (4-MEC).................... 25
4-Methyl-N-methylcathinone (mephedrone).............. 45
4-Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP).. 25
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3- 68
hydroxycyclohexyl]-phenol...........................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 53
phenol (cannabicyclohexanol or CP-47,497 C8-homolog)
5-Methoxy-3,4-methylenedioxyamphetamine.............. 25
5-Methoxy-N,N-diisopropyltryptamine.................. 25
5-Methoxy-N,N-dimethyltryptamine..................... 25
Acetyl-alpha-methylfentanyl.......................... 2
[[Page 55644]]
Acetyldihydrocodeine................................. 2
Acetylmethadol....................................... 2
Allylprodine......................................... 2
Alphacetylmethadol................................... 2
alpha-Ethyltryptamine................................ 25
Alphameprodine....................................... 2
Alphamethadol........................................ 2
alpha-Methylfentanyl................................. 2
alpha-Methylthiofentanyl............................. 2
alpha-Methyltryptamine (AMT)......................... 25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP).......... 25
alpha-Pyrrolidinopentiophenone ([alpha]-PVP)......... 25
Aminorex............................................. 25
Benzylmorphine....................................... 2
Betacetylmethadol.................................... 2
beta-Hydroxy-3-methylfentanyl........................ 2
beta-Hydroxyfentanyl................................. 2
Betameprodine........................................ 2
Betamethadol......................................... 4
Betaprodine.......................................... 2
Bufotenine........................................... 3
Cathinone............................................ 70
Codeine methylbromide................................ 5
Codeine-N-oxide...................................... 305
Desomorphine......................................... 25
Diethyltryptamine.................................... 25
Difenoxin............................................ 11,000
Dihydromorphine...................................... 3,990,000
Dimethyltryptamine................................... 35
Dipipanone........................................... 5
Fenethylline......................................... 5
gamma-Hydroxybutyric acid............................ 70,250,000
Heroin............................................... 50
Hydromorphinol....................................... 2
Hydroxypethidine..................................... 2
Ibogaine............................................. 5
Lysergic acid diethylamide (LSD)..................... 35
Marihuana............................................ 658,000
Mescaline............................................ 25
Methaqualone......................................... 10
Methcathinone........................................ 25
Methyldesorphine..................................... 5
Methyldihydromorphine................................ 2
Morphine methylbromide............................... 5
Morphine methylsulfonate............................. 5
Morphine-N-oxide..................................... 350
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide 25
(AKB48).............................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H- 25
indazole-3-carboxamide (ADB-PINACA).................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4- 25
fluorobenzyl)-1H-indazole-3-carboxamide (AB-
FUBINACA)...........................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1- 15
(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-
CHMINACA)...........................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H- 15
indazole-3-carboxamide (AB-PINACA)..................
N,N-Dimethylamphetamine.............................. 25
Naphthylpyrovalerone (naphyrone)..................... 25
N-Benzylpiperazine................................... 25
N-Ethyl-1-phenylcyclohexylamine...................... 5
N-Ethylamphetamine................................... 24
N-Hydroxy-3,4-methylenedioxyamphetamine.............. 24
Noracymethadol....................................... 2
Norlevorphanol....................................... 52
Normethadone......................................... 2
Normorphine.......................................... 40
Para-fluorofentanyl.................................. 5
Parahexyl............................................ 5
Phenomorphan......................................... 2
Pholcodine........................................... 5
Psilocybin........................................... 30
Psilocyn............................................. 30
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3- 25
carboxylate (5-fluoro-PB-22; 5F-PB-22)..............
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB- 25
22; QUPIC)..........................................
Tetrahydrocannabinols................................ 511,250
Thiofentanyl......................................... 2
Tilidine............................................. 25
[[Page 55645]]
Trimeperidine........................................ 2
------------------------------------------------------------------------
Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine.............................. 5
1-Piperidinocyclohexanecarbonitrile.................. 5
4-Anilino-N-phenethyl-4-piperidine (ANPP)............ 2,687,500
Alfentanil........................................... 17,750
Alphaprodine......................................... 3
Amobarbital.......................................... 25,125
Amphetamine (for conversion)......................... 21,875,000
Amphetamine (for sale)............................... 37,500,000
Carfentanil.......................................... 19
Cocaine.............................................. 275,000
Codeine (for conversion)............................. 50,000,000
Codeine (for sale)................................... 63,900,000
Dextropropoxyphene................................... 45
Dihydrocodeine....................................... 226,375
Dihydroetorphine..................................... 3
Diphenoxylate (for conversion)....................... 75,000
Diphenoxylate (for sale)............................. 1,337,500
Ecgonine............................................. 174,375
Ethylmorphine........................................ 5
Etorphine hydrochloride.............................. 3
Fentanyl............................................. 2,300,000
Glutethimide......................................... 3
Hydrocodone (for conversion)......................... 137,500
Hydrocodone (for sale)............................... 99,625,000
Hydromorphone........................................ 7,000,000
Isomethadone......................................... 5
Levo-alphacetylmethadol (LAAM)....................... 4
Levomethorphan....................................... 30
Levorphanol.......................................... 7,125
Lisdexamfetamine..................................... 29,750,000
Meperidine........................................... 6,250,000
Meperidine Intermediate-A............................ 6
Meperidine Intermediate-B............................ 32
Meperidine Intermediate-C............................ 6
Metazocine........................................... 19
Methadone (for sale)................................. 31,875,000
Methadone Intermediate............................... 34,375,000
Methamphetamine...................................... 2,061,375
------------------------------------------------------------------------
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled,
non-prescription product; 750,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 61,375 grams for
methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate...................................... 96,750,000
Morphine (for conversion)............................ 91,250,000
Morphine (for sale).................................. 62,500,000
Nabilone............................................. 18,750
Noroxymorphone (for conversion)...................... 17,500,000
Noroxymorphone (for sale)............................ 1,475,000
Opium (powder)....................................... 112,500
Opium (tincture)..................................... 687,500
Oripavine............................................ 35,000,000
Oxycodone (for conversion)........................... 8,350,000
Oxycodone (for sale)................................. 141,375,000
Oxymorphone (for conversion)......................... 29,000,000
Oxymorphone (for sale)............................... 7,750,000
Pentobarbital........................................ 35,000,000
Phenazocine.......................................... 6
Phencyclidine........................................ 38
Phenmetrazine........................................ 3
Phenylacetone........................................ 9,375,000
Racemethorphan....................................... 5
Racemorphan.......................................... 3
Remifentanil......................................... 4,200
Secobarbital......................................... 215,003
Sufentanil........................................... 6,255
Tapentadol........................................... 12,500,000
Thebaine............................................. 125,000,000
------------------------------------------------------------------------
[[Page 55646]]
List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion)........................... 1,000,000
Ephedrine (for sale)................................. 4,000,000
Phenylpropanolamine (for conversion)................. 44,800,000
Phenylpropanolamine (for sale)....................... 8,500,000
Pseudoephedrine (for conversion)..................... 7,000
Pseudoephedrine (for sale)........................... 224,500,000
------------------------------------------------------------------------
Aggregate production quotas for all other schedule I and II
controlled substances included in 21 CFR 1308.11 and 1308.12 remain at
zero.
Dated: September 10, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015-23199 Filed 9-15-15; 8:45 am]
BILLING CODE 4410-09-P
